Most providers describe their process as four reassuring verbs on a diagram. This page is the part that actually matters when you are deciding whether to hand a stranger your technical file: who is accountable for what, how we behave when a regulator says no, and how you leave if you want to.
Two weeks, fixed fee. A written route, a gap list and a costed plan. Ends with a document you own. Roughly one in five clients stops here, having got what they needed.
Structure designed, representative contracted, dossier assembled, submission made, regulator questions answered through to authorisation. Billed at milestones.
The calendar that keeps the authorisation alive: renewals, variations, new products, reporting deadlines. Annual, and it does not auto-renew.
There is no bundle and no minimum commitment. Each stage is quoted and agreed before it starts, and nothing rolls into the next automatically.
Four parties, and confusion between them is the most common reason projects go wrong. This is how we set it out in the engagement letter.
| Responsibility | You | Us | Local representative |
|---|---|---|---|
| Product safety and performance | Owner | — | — |
| Technical claims and clinical evidence | Owner | Reviews and challenges | — |
| Classification decision | Owner | Recommends, in writing | — |
| Holding the regulatory licence | — | — | Owner |
| Duties owed to the regulator | Via the file | — | Owner |
| Dossier assembly and format | Supplies content | Owner | — |
| Submission and correspondence | — | Owner | Files in its name |
| Deadlines and the project calendar | — | Owner | — |
| Paying official fees | Owner | Pays and recharges at cost | — |
| Post-market reporting | Owner | Runs the calendar | Owner, locally |
Two cells say "owner" on the same row deliberately. Post-market obligations genuinely sit on both the manufacturer and the local representative, and pretending otherwise is how incidents get reported late.
The same person runs your project from the kickoff call to the authorisation. You have their direct line, and they are in a European time zone, which matters when your representative is in Riyadh and you are in Manchester.
We do not drip-feed you twelve emails over three weeks. Queries are collected and sent as one list with a deadline, because that is how your QA lead can actually plan an afternoon around it.
Calls are followed by a written note of what was decided. Regulatory work has a way of being examined two years later by someone who was not there, including us.
If a submission is going to slip, or a representative is underperforming, or we got something wrong, you hear it by phone that week — not in the next scheduled update.
Reporting cadence. A short written status every two weeks during a live submission, and a quarterly note during maintenance covering anything the regulator has changed that touches your file. The quarterly note goes to clients whether or not anything happened — "nothing changed this quarter" is useful information in a market where things change without announcement.
A mutual non-disclosure agreement is signed before you send anything. If your legal team prefers its own template, we sign yours — we have no interest in arguing about NDAs, and a client who has to negotiate one before they can ask a question is a client who asks fewer questions.
Your technical documentation is shared with the local representative only to the extent the regulator requires, under the same confidentiality terms, and never with anyone else. We do not use client files as examples, we do not name clients without written permission, and we do not maintain a portfolio page for that reason.
Files are held for the duration of the engagement and for as long afterwards as the market's record-retention rules require — which in some jurisdictions runs to a decade past the last supply. On request we return everything and confirm deletion of what we are not obliged to keep.
It sometimes does. These are the five failures we actually see, and what we do about each. We would rather you read this now than discover our position in the middle of it.
The most common event, and not a failure.
We answer it. Deficiency questions are included in the project fee — we do not treat them as a change of scope, because a file that attracts no questions is rare and pricing as though it were is how firms create surprise invoices. Where the answer requires new evidence from you, we tell you what and why, and what it does to the timeline.
Rare, and usually foreseeable.
We tell you the grounds, whether they are curable, and what a resubmission would cost — including the honest answer where it is not worth doing. Our fee is not contingent on approval, which is precisely why we can give you that answer straight. If a refusal traces to our error, we correct it at our cost and say so in writing.
Slow, unresponsive, or out of their depth.
We contract them, so we manage them. If it is not fixable we run the replacement, and because we keep the licence-holding entity separate from distribution, replacing a representative does not disturb whoever is selling your product. The cost of the change depends on the market — in some it is administrative, in others the authorisation itself has to be rebuilt, and the assessment tells you which before you choose.
Fee schedules, review periods, document lists, whole regulators.
This happens more than the industry admits — one of our markets replaced its regulator and moved every service to a new portal within the last two years. We absorb the re-work into the fixed fee where it is a matter of effort. Where the change adds a new official cost or a new required document, that is passed through at cost and you see it before it is incurred.
Mid-project, for any reason or none.
You pay for milestones completed and nothing further. We hand over the dossier as it stands, the correspondence, the representative contacts and the shortlist, in a form another provider can pick up. There is no exit fee and no clause requiring you to explain yourself.
Fixed fees and fixed timelines only work if both parties hold up their end. These are the four things that actually determine whether a project runs to plan.
Tell us if you are also talking to someone else about the same market. Not because we mind — we frequently lose to a better-placed local firm and say so — but because two providers approaching the same representative on your behalf damages your position with them, and you will never see it happen.
Every figure we publish, and every figure in a document we give you, is traced to the regulator's own publication with the document name, its version and the date we checked it. Where an authority does not publish something openly — and several do not — we say so and confirm it directly with them, rather than repeating a plausible number from a consultancy blog.
We adopted the rule the hard way. When we verified our first two markets against primary sources, the figures circulating in the industry were wrong in both: review periods quoted at several times the published maximum, and a reliance route still being sold six years after the regulator stopped accepting applications through it. Pages are re-checked quarterly and after any circular affecting devices, and a market page does not go up until it has been checked at all.
The assessment is designed to be the cheap way to find out whether any of this suits you — including the possibility that it does not.
Check your routeOr reach us directly — mail@bcabusiness.co.uk · +44 7342 901002 · WhatsApp